The Centre has approved a 30% cap on trade margins for non-scheduled anti-cancer medicines, a move expected to reduce the prices of several cancer drugs by as much as 70% and generate annual savings of around ₹2,500 crore for patients. Cancer Drug Trade Margins Capped at 30% The new framework
